Literature DB >> 24828915

Fluorescent visualization of Src by using dasatinib-BODIPY.

Michael L Vetter1, Zijuan Zhang, Shuai Liu, Jinhua Wang, HaeYeon Cho, Jianming Zhang, Wei Zhang, Nathanael S Gray, Priscilla L Yang.   

Abstract

Many biological experiments are not compatible with the use of immunofluorescence, genetically encoded fluorescent tags, or FRET-based reporters. Conjugation of existing kinase inhibitors to cell-permeable fluorophores can provide a generalized approach to develop fluorescent probes of intracellular kinases. Here, we report the development of a small molecule probe of Src through conjugation of BODIPY to two well-established dual Src-Abl kinase inhibitors, dasatinib and saracatinib. We show that this approach is not successful for saracatinib but that dasatinib-BODIPY largely retains the biological activity of its parent compound and can be used to monitor the presence of Src kinase in individual cells by flow cytometry. It can also be used to track the localization of Src by fixed and live-cell fluorescence microscopy. This strategy could enable generation of additional kinase-specific probes useful in systems not amenable to genetic manipulation or could be used together with fluorescent proteins to enable a multiplexed assay readout.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cell recognition; fluorescent probes; kinase inhibitors; proteins; signal transduction

Mesh:

Substances:

Year:  2014        PMID: 24828915      PMCID: PMC4130483          DOI: 10.1002/cbic.201402010

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  34 in total

Review 1.  Ba/F3 cells and their use in kinase drug discovery.

Authors:  Markus Warmuth; Sungjoon Kim; Xiang-ju Gu; Gang Xia; Francisco Adrián
Journal:  Curr Opin Oncol       Date:  2007-01       Impact factor: 3.645

2.  A guided tour into subcellular colocalization analysis in light microscopy.

Authors:  S Bolte; F P Cordelières
Journal:  J Microsc       Date:  2006-12       Impact factor: 1.758

3.  Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.

Authors:  Matthäus Getlik; Christian Grütter; Jeffrey R Simard; Sabine Klüter; Matthias Rabiller; Haridas B Rode; Armin Robubi; Daniel Rauh
Journal:  J Med Chem       Date:  2009-07-09       Impact factor: 7.446

Review 4.  Endosomal trafficking of Src tyrosine kinase.

Authors:  Emma Sandilands; Margaret C Frame
Journal:  Trends Cell Biol       Date:  2008-07       Impact factor: 20.808

Review 5.  Chemical biology-based approaches on fluorescent labeling of proteins in live cells.

Authors:  Deokho Jung; Kyoungmi Min; Juyeon Jung; Wonhee Jang; Youngeun Kwon
Journal:  Mol Biosyst       Date:  2013-05

6.  Green fluorescent protein as a marker for gene expression.

Authors:  M Chalfie; Y Tu; G Euskirchen; W W Ward; D C Prasher
Journal:  Science       Date:  1994-02-11       Impact factor: 47.728

7.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Authors:  John S Tokarski; John A Newitt; Chieh Ying J Chang; Janet D Cheng; Michael Wittekind; Susan E Kiefer; Kevin Kish; Francis Y F Lee; Robert Borzillerri; Louis J Lombardo; Dianlin Xie; Yaqun Zhang; Herbert E Klei
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.

Authors:  Scott A Laurie; Glenwood D Goss; Frances A Shepherd; M Neil Reaume; Garth Nicholas; Lindsay Philip; Lisa Wang; Joerg Schwock; Vera Hirsh; Amit Oza; Ming-Sound Tsao; John J Wright; Natasha B Leighl
Journal:  Clin Lung Cancer       Date:  2013-10-26       Impact factor: 4.785

9.  Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.

Authors:  Miriam Benezra; Dolores Hambardzumyan; Oula Penate-Medina; Darren R Veach; Nagavarakishore Pillarsetty; Peter Smith-Jones; Evan Phillips; Tatsuya Ozawa; Pat B Zanzonico; Valerie Longo; Eric C Holland; Steven M Larson; Michelle S Bradbury
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

10.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.

Authors:  Oliver Hantschel; Uwe Rix; Uwe Schmidt; Tilmann Bürckstümmer; Michael Kneidinger; Gregor Schütze; Jacques Colinge; Keiryn L Bennett; Wilfried Ellmeier; Peter Valent; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-07       Impact factor: 11.205

View more
  9 in total

1.  Development of inverse electron demand Diels-Alder ligation and TR-FRET assays for the determination of ligand-protein target occupancy in live cells.

Authors:  Jasmina Marjanovic; Aleksandra Baranczak; Violeta Marin; Henning Stockmann; Paul L Richardson; Anil Vasudevan
Journal:  Medchemcomm       Date:  2017-02-21       Impact factor: 3.597

2.  Fluorescent Properties of BODIPY Sensors Based on Photoinduced Electron Transfer.

Authors:  Yu S Marfin; M V Shipalova; V O Kurzin; K V Ksenofontova; A V Solomonov; E V Rumyantsev
Journal:  J Fluoresc       Date:  2016-08-16       Impact factor: 2.217

3.  Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.

Authors:  Frank E Kwarcinski; Kristoffer R Brandvold; Sameer Phadke; Omar M Beleh; Taylor K Johnson; Jennifer L Meagher; Markus A Seeliger; Jeanne A Stuckey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2016-03-01       Impact factor: 5.100

4.  A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib.

Authors:  Melinda Wang; Harikrishna Kommidi; Umberto Tosi; Hua Guo; Zhiping Zhou; Melanie E Schweitzer; Linda Y Wu; Ranjodh Singh; Shengqi Hou; Benedict Law; Richard Ting; Mark M Souweidane
Journal:  Mol Cancer Ther       Date:  2017-10-04       Impact factor: 6.261

Review 5.  Fluorescent kinase inhibitors as probes in cancer.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Chem Soc Rev       Date:  2021-07-22       Impact factor: 60.615

6.  Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.

Authors:  Norihito Shibata; Naoki Miyamoto; Katsunori Nagai; Kenichiro Shimokawa; Tomoya Sameshima; Nobumichi Ohoka; Takayuki Hattori; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  Cancer Sci       Date:  2017-06-19       Impact factor: 6.716

7.  Kinase-templated abiotic reaction.

Authors:  J Saarbach; E Lindberg; S Folliet; S Georgeon; O Hantschel; N Winssinger
Journal:  Chem Sci       Date:  2017-05-24       Impact factor: 9.825

8.  Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy.

Authors:  Xinyu Song; Xiaoyue Han; Fabiao Yu; Xiaoyu Zhang; Lingxin Chen; Changjun Lv
Journal:  Theranostics       Date:  2018-03-08       Impact factor: 11.556

9.  Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.

Authors:  Norihito Shibata; Kenichiro Shimokawa; Katsunori Nagai; Nobumichi Ohoka; Takayuki Hattori; Naoki Miyamoto; Osamu Ujikawa; Tomoya Sameshima; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  Sci Rep       Date:  2018-09-10       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.